Growth Hormone & PerformanceGrade A
Tesamorelin
Also known as Egrifta
The only GHRH analog with an FDA-approved indication for reducing visceral adipose tissue.
- Regulatory status
- FDA approved (HIV lipodystrophy)
- Half-life
- ~26–38 minutes
- Route
- Subcutaneous, daily
- Evidence
- Multiple randomized controlled trials in humans
Mechanism of action
Stabilized GHRH analog that restores physiologic GH pulsatility.
Studied and reported uses
- Visceral fat reduction
- Metabolic markers in lipodystrophy
Dosing information
Approved dose1.4 mg (2 mg formulation) daily
Ranges are reported from literature and clinical labeling for reference only. They are not a dosing recommendation.
Side effects
- Arthralgia
- Injection-site erythema
- Peripheral edema
- Glucose elevation
Research evidence
Phase 3
~15% visceral adipose tissue reduction at 26 weeks.
NASH substudy
Reduced liver fat in people with HIV.